Europe’s health technology assessment regime has entered a new era. Since January 2025, oncology drugs and advanced therapies ...

Japan’s largest drugmaker Takeda has presented data from two global Phase III double-blind, placebo-controlled studies of ...

The US Food and Drug Administration has approved Janssen Biotech’s Inlexzo (gemcitabine) intravesical system for adults with ...

Sobi (STO: SOBI) said Friday that the US Food and Drug Administration has accepted its biologics license application for ...

Danish diabetes and obesity care giant Novo Nordisk today announced a company-wide transformation to simplify its ...

Alchemab Therapeutics has begun its first-in-human study of ATLX-1282, a potential treatment for amyotrophic lateral ...

The US Department of Health and Human Services (DHSS) and the Food and Drug Administration (FDA) yesterday announced sweeping ...

Cambridge, USA-based CAMP4 Therapeutics today announced that it has entered into definitive securities purchase agreements ...

The US Health Resources and Services Administration’s (HRSA) rebate model pilot marks an important first step in bringing ...

Dublin (Ireland), and Hamilton (Bermuda), dedicated to developing therapies for central nervous system and rare diseases, ...

Lundbeck (LUND: CO)) said Tuesday it will withdraw from 27 international markets, shifting its commercial operations to Swixx ...

Its lead candidate, LB-102, is an oral reformulation of the antipsychotic amisulpride, designed for once-daily dosing with ...